13 May 2020 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its strategy to create a global nutraceuticals brand, with a focus on higher margin, consumer branded products, new management team, capital raising and FY 20 outlook.
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
01 May 2020 - Acorn Capital, Head of Portfolio Implementation and Portfolio manager (Healthcare and Biotechnology sectors) Paul Palumbo looks the microcap sector and the recent market sell off and discusses the outlook for next 6 months and longer term.
28 Apr 2020 - BrainChip Holdings (ASX:BRN BrainChip Holdings (ASX:BRN) CEO Lou DiNardo talks about its Akida integrated circuit, its advantages in event-based convolutional (e-conv) networks, applications and its move to wafer production and first engineering samples by Q3 2020.
27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
24 Apr 2020 - Telix Pharmaceuticals (ASX:TLX), Chief Business Officer, David Cade talks about its prostate cancer imaging product, diagnostic and therapeutic products, partners and key priorities for 2020.
21 Apr 2020 - Cashwerkz (ASX:CWZ) newly appointed CEO, Jon Lechte talks about what attracted him to the role, and plans to drive growth for cash and fixed income products in a more uncertain economic environment.
15 Apr 2020 - MLC Senior Economist Bob Cunneen discusses the ongoing impact of the coronavirus on markets including central bank and government measures.
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
